PBAC submission: subcutaneous ocrelizumab
MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ocrelizumab (Ocrevus®) via subcutaneous (SC) delivery on the Pharmaceutical [...]
MS Australia’s response to the 2025-26 Federal Budget
MS Australia has undertaken an analysis of the 2025-26 Budget to explore how it will impact the lives of people living with MS.
Submission relating to ublituximab (Briumvi®) to PBAC meeting May 2025
MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the [...]
Pre-Budget Submission 2025-26
MS Australia’s 2025-26 Pre-Budget Submission advocates for strategic investments to support over 33,300 Australians living with MS. Key funding asks include $8M for a National MS Biobank, $300M [...]
Submission relating to ravulizumab (Ultomiris®) to PBAC meeting November 2024
MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the [...]
